The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

Mohammed Altyb Alshykh  
Alzaiem Alazhari University

Mohammed Elmujtba Adam Essa (Awadali818@yahoo.com)  
MCRI  https://orcid.org/0000-0002-1050-2771

Yousra Abdelmoniem Suleiman  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Sherihan Mohammed Elkundi Osman  
Al Fashir University Faculty of Medicine

Mustafa Mohamed Ali Hussein  
Al Fashir University Faculty of Medicine

Sadia Kamal Albadawi Mohamed  
University of Gezira

Shiema Alm El Abdrahim  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Leena Habeeb Allah Osman  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Saja Hassan Mohamed  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Salma Ismaeel Rahama  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Saneyya Alsir Ali  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Sadiya Aminu Abdullahi  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Suha Abdallah Musa  
Omdurman Islamic University Faculty of Medicine and Health Sciences

Abdelkareem A. Ahmed (kareemo1511@gmail.com)  
University of Nyala

Research article
Abstract

Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan.

Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy.

Result The peak prevalence of the patients was found in Al-Gazeera state, and the least in Al-Gadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. In 50% of patients the cancer recurred after 1-2 months, 32.2% after 3-4 months and 17.8% after 5-6 months. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary.

Conclusion Our findings suggested that, Al-Gazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.

1. Background

Ovarian cancer is one of the most widely distributed malignancies worldwide and is considered the lethal gynaecological type and the fifth leading cause of cancer death (1–4), because of its high recurrence rate which is resist to chemotherapy (5). Nearly, 3 out of 4 of epithelial ovarian cancer (EOC) type present with late advanced stage (6). The lifetime risk of developing ovarian cancer in general population is 1.4 per cent and the mean age of presentation is 64 years, even though its incidence are varied by regions (7). Many factors play major role in the disease development and these includes advance age (8, 9), genetics associations (10–12), early menstruation (13), late menopause (14) and hormonal therapy (15). An ovarian tumors are mainly primary but secondaries from colon (16), stomach (17), small intestine (18), pancreas (6), breast (19) and even thyroid cancer (20) are also common. The world health organization (WHO) classified the ovarian cancer to many types based on their histological principles (21), the high grade serous ovarian carcinoma are considered the most common type (22). The current management of ovarian tumours at the early stage includes surgical removal (23, 24), followed by combination platinum/taxane chemotherapy (25, 26), while the others two thirds of patients which presented with advance late stage respond to the conventional therapy (27). 60% of them will have disease recurrence and up to 90% will die eventually (6). The survival rate in early stage patients approaches 90%, however most of ovarian tumors diagnosed in their advance stage (28). Ovarian tumors can originate from any site of the following potential three: fallopian tube (29), mesothelium lined peritoneal cavity (30) and ovary surfaces (31). The risk of metastasis of ovarian cancer depends on the stage and histological subtype of the tumor (32). Patients with recurrent EOC are characterized by an initial platinum therapy response (33). Women with ovarian cancer have a good response to standard platinum treatment (34),
although majority of patients with late stage will ultimately relapse (35), and resist the first line treatment (35, 36). Platinum resistant ovarian cancer is defined as disease recurrence within 6 months of completion of first-line platinum-based chemotherapy (37), and when cancer actually demonstrate growth during treatment or no frankly evidence of cancer regression after 4–6 cycles of therapy by platinum treatment (38). The platinum resistance has widely been demonstrated recently for ovarian cancer (5) and included many chemotherapy agents (39).

The decision of considering second-line chemotherapy in recurrent ovarian cancer patients is not yet fully clear, and this is related to the absence of standard chemotherapy to the recurrent ovarian cancer or the platinum-resistant (5). Until now oncologists are not capable to understand the genetic events for developing of ovarian tumors and it remains unknown. This is due to lack of an experimental model system for understanding and studying human ovarian tumor in contrast to several studies conducted using the animal models for ovarian carcinogenesis (40–43).

There are no information about the chemotherapy treatment of ovarian cancer in Sudan, Therefore we are aiming to determine the effectiveness of second line chemotherapy in treatment of recurrent ovarian cancer in Sudan, determine the most effective type of second line chemotherapy, the most common histological types and most common sites of metastasis.

2. Methods

This is a retrospective cross sectional hospital study carried out at The Radiation and Isotopes Centre Khartoum (RICK), Khartoum, Sudan, which was conducted between the periods of 2013–2017 for a number of 62 recurrent ovarian cancer patients. The data was selected based on specific criteria included only the patients who treated with the second line chemotherapy platinum resistance and platinum refractory. The designated questionnaire contains information that confirm cancer diagnosis by clinical oncologist including patient age, clinical presenting features, occupation, geographical, ethnic distributions, histopathological reports for ovarian cancer type, computer imaging (CT), CA 125 value before and after treatment receiving, the interval time between full course given treatment and the cancer recurrence, and number of chemotherapy cycles. The patients received multiple agents of second line chemotherapy such as Gemzar in dosage of 1 gram as follow: each 7 days for 3 time then repeated every 3 weeks, carboplatin in a dosage of 30 mg/m2 every 4 weeks for 3–6 cycles, Docetaxel 60–75mg/m2 intravenous (IV) administration over 1 hour followed by carboplatin AUC 5–6 IV over 1 hour day 1 repeated every 3 weeks x 6 cycle. The ethical approval and formal consent was obtained from all the patients, the federal ministry of health (FMOH) and the ethical committee of the RICK for scientifically purpose.

2.3 Statistical analysis

Statistical software package SPSS version 17.0 has been used to analyze data of second line chemotherapy platinum resistance ovarian cancer such as percentages, frequency, valid percent and
cumulative percent. P value calculations for statistical significant testing, evaluations data were analyzed by one-way analysis of variance (ANOVA), the level of statistical significance was set as $P< 0.05$.

3. Results

Gemcitabine (Gemzar) found to be the most widely used chemotherapeutic agent by 72.6 % of all the studied patients, followed by Gemzar nevalbin 8.1 %, Gemzar cyclophosphamide 8.1 %, both Taxol & carboplatin 6.5 %, then Gemzar oxaliplatin 3.2 % and finally Docetaxel 1.6% (Table 1). All patients received various cycles of chemotherapy, in about 40.3 % of all the patients received 3 cycles of the chemotherapy. Patients who received 5 cycles and 1 cycle have the fewest percentage between all the patients only 6.4% of each. The other patients received different cycles of chemotherapy as follow: 21% of patients received 6 cycles, 17.7% have received 2 cycles and only 14.5% of the patients received 4 cycles (Table 2). The most common ovarian metastatic site distinguished before initiation of the second line platinum resistance chemotherapy was the pelvis by 43.5%. Abdominal ascites 24.2%, combined ascites and pelvic mass 16.1%, both pelvic and liver metastasis in same percentage 4.9%, and also liver metastasis with ascites with equal per cent 3.2%, pelvic and peritoneal metastasis 3.2%, isolated lung metastasis 3.2%, and lastly ascites with pelvic and lung metastasis together 1% (Table 3).

Regarding the chemotherapy agents effectiveness, patients who treated by Gemzar showed 42.2 % zero mass in the CT abdomen report, 46.7 % decreased masses size and 11.1% continuous increased mass size (Table 4). The most common histopathological type isolated from the patients were serous cyst adenocarcinoma in 90.3% of all the patients, followed by mucinous adenocarcinoma 3.2%, and the remaining types in equal percent 1.6, which are transitional cell adenocarcinoma, endometrial adenocarcinoma, serous papillary adenocarcinoma and clear cell carcinoma (Table 5).

For the tumor marker CA 125, there were 24.1 % of patients were sustained values before and after treatment. About 25.8 % have returned into the normal value and 1.6 % of the patients showed increases in the level of CA125. The rest of the patients did not achieve the normal levels of CA125. Overall, 79.4 % of patients who received the second line chemotherapy were reached the normal range of CA125 value (0–34 U/mL). Regarding the age groups, there were 37.1 % of the patients were above of 55 years old (Fig. 1). We also observed that both AlGazeera and Khartoum states had the highest and equal incidence among all the patients by 19 % (Fig. 2), followed Kordoufan states 16 %, white Nile state 15 %, Darfur states 8 %, Kassala state 8 %, Abuhammed city 7 %, Algaradif 5 % and Republic of South Sudan 3 % (Fig. 2). In Half of the patients the tumor recurred after 1–2 months from full treatment course of the chemotherapy, followed by 32.3 % after 3–4 months and 17.7 % after 5–6 months (Fig. 3). After receiving the second line chemotherapy, 30.6 % of the patients showed complete mass disappearing with 54.8 % of regression in the mass size and 14.5% had failed to respond to treatment with increase in tumor size (Fig. 4).

4. Discussion
Many factors can contribute in the etiology of ovarian tumors, and these may include genetic mutation such as Breast Cancer (BRCA) mutation (44–47), postmenopausal stage (48), talcum powder (49) and hormonal change in advance age (50). Generally this type of cancer is considered to be one of the most devastating tumors, due to the lack of specific clinical symptoms related to it, until to be spread beyond level of the primary site and become difficult to treat (50). The current study demonstrated platinum resistance ovarian cancer patients for four years period of time. The study showed that an age group above 55 years was represented more than the one third of the patients. Our results are similar to earlier studies which reported that malignant ovarian cancer age incidence rate above 55 years (5, 51–53). Other reports revealed the age group above the 65 years, constitutes 30–40 % of all ovarian cancer patients (22, 54). This higher prevalence of age linked ovarian malignancy may related to menopausal period (14) and advance age (50).

Here we reported for the first time that both Al Gazeera and Khartoum states had the same incidence 19 %. But taken in account the population density between two states, the prevalence were higher in Al Gazeera state compared to Khartoum state 2:1 respectively (51). The second line platinum resistance chemotherapy included many types such as liposomal pegylated doxorubicin (55), topotecan (56), paclitaxel (57), oral etoposide (58) and gemcitabine (51). All of these chemotherapy agents have similar response treatment rate which is about 10 % (5). Our findings showed that the Gemzar had better response among other chemotherapeutic agents by 42.2% of the studied patients treated. In addition, Gemzar treatment showed complete response by 46.7% with partially shrinkage of tumor size and the remaining 11.1% of the patients resisted the treatment. Our findings mismatch with previous study that reported less effectivity of Gemzar to ovarian cancer patients, as only 18.5% of cases showed complete response, 29.6% with partially response and 51.9% with disease progression (22). This could be due to the antitumor activity and higher tolerability against toxicity (54, 59).

The serous cyst adenocarcinomas are the most isolated histological type, and had been identified in 90.3 % of our studied patients. Our results are in agreement with those reported from others studies which show the same isolated histological type (22, 50, 60–62). This may related to higher significant frequency number of abnormality genetics copy in adenocarcinoma type (63, 64), and absence of BRCA function (65). The pelvic mass was the most common metastatic site of ovarian cancer in our patients. And this is related to the unique nature of the ovarian tumor itself, where it tends to spread more easily by passive mechanism of the physiological movement to the peritoneum and omentum through the peritoneal fluids (30). Therefore, it disseminates by the pelvic and para-aortaic lymph nodes but rarely through the vasculature (66). Unlike other types of cancer such as colon and breast cancer, and hence the pelvic organs are the most affected site of ovarian carcinoma (67, 68). Generally, the study estimated the incidence of the patients not the prevalence; it’s also included some resident patients from south Sudan country. Most of our studied patients received three cycle of treatment but no complication had been observed as side effects despite of other studies who recorded many, for instance ascites and edema especially after the fifth cycle (69). Yet, no certain explanation had been identified.
The interval time duration between full treatment and relapse had been used to determine the condition response of the second line treatment (70). The tumor relapse within three months is considered platinum refractory, six months resistant and beyond that as sensitive (70). According to this classification, our study categorized patients into two groups, platinum refractory and platinum resistant in equal percent.

The tumor marker Cancer antigen (CA) 125 is considered a gold standard tumor marker in ovarian cancer (71). Elevated levels of CA125 are used for monitoring treatment response (72), relapse (73), and progression of the disease (74). In our study, we detected 25.8% of the patients returned their normal value of the CA125 (0–34 U/ml) after receiving the first line platinum treatment in contrary to 79.4% who achieved the same value after receiving second line. Our results are in line with other study that revealed better CA125 response in second line platinum treatment than initial chemotherapy (75). The alterations in CA 125 values depend on different factors, such as agents interference with metabolism of the CA125 (76), tumor clone mix (76) and agent affinity for tumor tissues expression of CA125 (76).

The limitation of our study is no BRCA testing was available to the patients.

5. Conclusion

Age group above 55 years was the commonest affected age group. Al Gazeera state is the most geographical region treated by the second line platinum resistance. Serous adenocarcinoma is the most histological finding and pelvic organs are the most vulnerable organs to metastasise. Gemzar was found to be the most abundant chemotherapy agent been used and showed more than one third curable rate. The value of CA125 has reduced markedly after treatment. These findings could enhance establishing a new guideline for treatment of ovarian cancer by second line chemotherapy.

6. Declarations

6.1. Ethical approval and consent to participate

Obtained from federal ministry of health (FMOH), Khartoum, Sudan.

6.2. Consent for publication

Not applicable

6.3. Availability of data and materials

All the data used in the study are available from the first and corresponding author on reasonable request
6.4. Competing of interest

All authors declare that they have no any conflict of interest.

6.5. Funding

No fund have been received

6.6. Author contributions

The scientific writing of the manuscript along with the data analysis were handled by Dr. Mohammed Elmujtba Adam Essa, Dr. Mohammed Altyb Alshykh, Dr. Sherihan Mohammed Elkundi Osman and Dr. Mustafa Mohamed Ali Hussein, Dr. Sadia Kamal Albadawi Mohamed, The data were collected from the hospital records by Shiemaa Emad Abdelrahim, Leena Habeeb Allah Osman, Saja Hassan Mohamed, Salma Ismaeel Rahama, Saneyya Alsir Ali, Sadiya Aminu Abdullahi and Suha Abdallah Musa. Dr. Yousra Abdelmoniem Suleiman is the clinical oncologist who supervised the treatment of the patients. The study was supervised by Prof. Abdelkareem A. Ahmed.

6.7. Acknowledgments

The authors are highly grateful to RICK hospital administration for their support to conduct this research.

7. References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009;59(4):225–49.

2. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncology. 2014;15(11):1207–14.

3. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology. 2014;6(5):229–39.

4. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. Journal of experimental & clinical cancer research: CR. 2012;31:14.

5. Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert opinion on investigational drugs. 2010;19(11):1339–54.
6. Doganay M, Topcu HO, Kokanali MK, Guzel AI, Oskovi A, Akbay S, et al. Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. Journal of experimental therapeutics & oncology. 2015;11(1):23–6.

7. Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. International journal of cancer. 2017;140(11):2451–60.

8. Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, et al. Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments. Aging and disease. 2017;8(5):677–84.

9. Loughran EA, Leonard AK, Hilliard TS, Phan RC, Yemc MG, Harper E, et al. Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue. Neoplasia. 2018;20(6):621–31.

10. Negura L, Dusa CP, Balmus MI, Azoicai D, Negura AM, Marinca MV, et al. BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2015;56(2):379–85.

11. O’Neill SM, Rubinstein WS, Wang C, Yoon PW, Acheson LS, Rothrock N, et al. Familial risk for common diseases in primary care: the Family Healthware Impact Trial. American journal of preventive medicine. 2009;36(6):506–14.

12. Ruiz-Flores P, Calderon-Garciduenas AL, Barrera-Saldana HA. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2001;53(1):46–64.

13. La Vecchia C. Ovarian cancer: epidemiology and risk factors. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2017;26(1):55–62.

14. Moszynski R, Zywica P, Wojtowicz A, Szubert S, Sajdak S, Stachowiak A, et al. Menopausal status strongly influences the utility of predictive models in differential diagnosis of ovarian tumors: an external validation of selected diagnostic tools. Ginekologia polska. 2014;85(12):892–9.

15. Daniilidis A, Karagiannis V. Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy. Hippokratia. 2007;11(2):63–6.

16. Shin DW, Choi YJ, Kim HS, Han KD, Yoon H, Park YS, et al. Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea. Diseases of the colon and rectum. 2018;61(11):1250–7.

17. Koyama T, Mikami Y, Saga T, Tamai K, Togashi K. Secondary ovarian tumors: spectrum of CT and MR features with pathologic correlation. Abdominal imaging. 2007;32(6):784–95.
18. Andresen DM, Pedersen FH, Rasmussen KL. Adenocarcinoma of the small intestine mistaken as a primary ovarian cancer. Archives of gynecology and obstetrics. 2001;265(4):214–5.

19. Gavriilidis P, Ananiadis A, Theodoulidis V, Toskas I, Barbanis S. Ovarian metastasis from breast invasive ductal carcinoma. Hippokratia. 2012;16(4):391.

20. Brogioni S, Viacava P, Tomisti L, Martino E, Macchia E. A special case of bilateral ovarian metastases in a woman with papillary carcinoma of the thyroid. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2007;115(6):397–400.

21. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, et al. Histological classification of ovarian cancer. Medical electron microscopy: official journal of the Clinical Electron Microscopy Society of Japan. 2003;36(1):9–17.

22. Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer treatment reviews. 2015;41(2):136–43.

23. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic oncology. 2007;106(3):482–7.

24. Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. The Cochrane database of systematic reviews. 2013(2):CD008765.

25. Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecologic oncology. 2003;90(3 Pt 2):S8–15.

26. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecologic oncology. 2003;90(3 Pt 2):S39–44.

27. Kroep JR. Advances in epithelial ovarian cancer therapy. Current pharmaceutical design. 2012;18(25):3735–40.

28. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, et al. Ovarian cancer: pathology, biology, and disease models. Frontiers in bioscience. 2009;14:2089–102.

29. Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin of ovarian cancer. American journal of obstetrics and gynecology. 2013;209(5):409–14.

30. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–64.

31. Lengyel E. Ovarian Cancer Development and Metastasis. The American journal of pathology. 2010;177(3):1053–64.
32. Heitz F, Harter P, Ataseven B, Heikaus S, Schneider S, Prader S, et al. Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaoortic Lymphadenectomy. Annals of surgical oncology. 2018;25(7):2053–9.

33. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1994;12(9):1748–53.

34. Cannistra SA. Cancer of the ovary. The New England journal of medicine. 1993;329(21):1550–9.

35. Bookman MA, McGuire WP, 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1996;14(6):1895–902.

36. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. The New England journal of medicine. 1996;334(1):1–6.

37. Colombo N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJC supplements: EJC: official journal of EORTC, European Organization for Research and Treatment of Cancer [et al]. 2014;12(2):7–12.

38. Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic oncology. 2011;122(1):116–20.

39. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769–92.

40. Adams AT, Auersperg N. Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer research. 1981;41(6):2063–72.

41. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. Journal of the National Cancer Institute. 1992;84(8):592–601.

42. Piquette GN, Timms BG. Isolation and characterization of rabbit ovarian surface epithelium, granulosa cells, and peritoneal mesothelium in primary culture. In vitro cellular & developmental biology: journal of the Tissue Culture Association. 1990;26(5):471–81.

43. Nicosia SV, Johnson JH, Streibel EJ. Growth characteristics of rabbit ovarian mesothelial (surface epithelial) cells. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists. 1985;4(1):58–74.
44. Spriggs DR, Longo DL. Progress in BRCA-Mutated Ovarian Cancer. The New England journal of medicine. 2018;379(26):2567–8.

45. Mehta A, Vasudevan S, Sharma SK, Kumar D, Panigrahi M, Suryavanshi M, et al. Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India. Cancer management and research. 2018;10:6505–16.

46. Grynberg M, Dagher Hayeck B, Papanikolaou EG, Sifer C, Sermondade N, Sonigo C. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. Human reproduction. 2018.

47. Girardi F, Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, et al. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in medicine: official journal of the American College of Medical Genetics. 2018.

48. Shen F, Chen S, Gao Y, Dai X, Chen Q. The prevalence of malignant and borderline ovarian cancer in pre- and post-menopausal Chinese women. Oncotarget. 2017;8(46):80589–94.

49. Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer S, Australian Ovarian Cancer Study G. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. International journal of cancer. 2008;122(1):170–6.

50. Abuidris DO, Weng HY, Elhaj AM, Eltayeb EA, Elsanousi M, Ibnoof RS, et al. Incidence and survival rates of ovarian cancer in low-income women in Sudan. Molecular and clinical oncology. 2016;5(6):823–8.

51. Meisel JL, Hyman DM, Jotwani A, Zhou Q, Abu-Rustum NR, Iasonos A, et al. The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic oncology. 2015;136(3):505–11.

52. van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecologic oncology. 2012;125(3):649–54.

53. Doll KM, Puliaev R, Chor J, Roston A, Patel UA, Patel A. Detection of gynecologic cancers in indigent women in an urban inner-city hospital. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2012;22(7):1113–7.

54. Bai H, Sha G, Cao D, Yang J, Chen J, Wang Y, et al. Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases. Medicine. 2015;94(27):e1121.

55. Kanwal U, Bukhari NI, Rana NF, Rehman M, Hussain K, Abbas N, et al. Doxorubicin-loaded quaternary ammonium palmitoyl glycol chitosan polymeric nanoformulation: uptake by cells and organs. International journal of nanomedicine. 2019;14:1–15.
56. Herzog TJ, Holloway RW, Stuart GC. Workshop: options for therapy in ovarian cancer. Gynecologic oncology. 2003;90(3 Pt 2):S45–50.

57. Zhai J, Luwor RB, Ahmed N, Escalona R, Tan FH, Fong C, et al. Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer. ACS applied materials & interfaces. 2018;10(30):25174–85.

58. Kucukoner M, Isikdogan A, Yaman S, Gumusay O, Unal O, Ulas A, et al. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology. Asian Pacific journal of cancer prevention: APJCP. 2012;13(8):3973–6.

59. Kodaz H, Hacibekiroglu I, Turkmen E, Erdogan B, Elpen C, Uzunoglu S, et al. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer. Tumori. 2015;101(1):36–40.

60. Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, et al. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2016;26(4):626–31.

61. Anfinan N, Sait K, Ghatage P, Nation J, Chu P. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre. Archives of gynecology and obstetrics. 2011;284(3):731–5.

62. Kheiri SA, Kunna A, Babiker AY, Alsuhaibani SA, Ahmed RY, Alsammani MA. Histopathological Pattern and Age Distribution, of Malignant Ovarian Tumor among Sudanese Ladies. Open access Macedonian journal of medical sciences. 2018;6(2):237–41.

63. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer research. 1995;55(24):6172–80.

64. Micci F, Haugom L, Abeler VM, Davidson B, Trope CG, Heim S. Genomic profile of ovarian carcinomas. BMC cancer. 2014;14:315.

65. Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer research. 2003;63(2):417–23.

66. Eisenkop SM, Spirtos NM. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecologic oncology. 2001;82(1):143–9.

67. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014;32(13):1302–8.
68. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95.

69. Ata A, Gurses I, Kiykim A, Arican A. Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer. The American journal of case reports. 2012;13:268–70.

70. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. The oncologist. 2002;7 Suppl 5:20–8.

71. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. Journal of ovarian research. 2009;2:13.

72. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58(3):308–12.

73. Bast RC, Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer. 2010;116(12):2850–3.

74. Chaudhry P, Srinivasan R, Patel FD, Gopalan S, Majumdar S. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. International journal of cancer. 2008;122(8):1716–21.

75. Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic oncology. 2018;150(2):239–46.

76. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA−125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(20):4051–8.

8. Tables

Table: 1 illustrate the second line chemotherapy agents.
| Second line chemotherapy agents     | Frequency | Per cent |
|-------------------------------------|-----------|----------|
| Gemzar                              | 45        | 72.6 %   |
| Taxol & carboplatin                 | 4         | 6.5 %    |
| Docetaxel                           | 1         | 1.6 %    |
| Gemzar nevalbin                     | 5         | 8.1 %    |
| Gemzar oxaliplatin                  | 2         | 3.2 %    |
| Gemzar cyclophosphamide             | 5         | 8.1 %    |
| Total                               | 62        | 100 %    |

Table: 2 show the frequencies of each cycle of the second line platinum resistance chemotherapy received by the ovarian cancer patients.

| Chemotherapy cycles | Frequency | %    |
|---------------------|-----------|------|
| 1                   | 2         | 3.2 %|
| 2                   | 11        | 17.7 %|
| 3                   | 25        | 40.3 %|
| 4                   | 9         | 14.5 %|
| 5                   | 2         | 3.2 %|
| 6                   | 13        | 21%   |
| Total               | 62        | 100 %|

Table: 3 show The CT abdomen reports of the patients.
| Computer tomography scan findings                  | Per cent | Frequency |
|---------------------------------------------------|----------|-----------|
| Pelvic mass                                       | 43.5 %   | 27        |
| Lung metastasis                                   | 3.2 %    | 2         |
| Ascites                                           | 24.2 %   | 15        |
| Pelvic mass & liver metastasis                    | 4.9 %    | 3         |
| Pelvic mass & peritoneal metastasis               | 3.2 %    | 2         |
| Pelvic mass & Ascites                             | 16.1 %   | 10        |
| Liver metastasis & Ascites                        | 3.2 %    | 2         |
| Pelvic mass, lung metastasis & Ascites            | 1.6 %    | 1         |
| **Total**                                         | **100 %**| **62**    |

**Table: 4 demonstrate the metastasis site, percent and frequencies of the patients before receiving the second line chemotherapy.**
| Chemotherapy agent                  | Complete responded | Partial responded | Failed responded | to | Total |
|------------------------------------|--------------------|-------------------|------------------|----|-------|
| Gemzar                             | 19                 | 21                | 5                | 45 | 45 %  |
|                                    | 42.2 %             | 46.7 %            | 11.1 %           | 100% |
| Taxol & carboplatin                | 0                  | 4                 | 0                | 4  | 100 % |
|                                    | 0.00 %             | 100 %             | 0.00 %           | 100% |
| Docetaxol                          | 0                  | 1                 | 0                | 1  | 100 % |
|                                    | 0.00 %             | 100 %             | 0.00 %           | 100% |
| Gemzar & nevalbin                  | 0                  | 3                 | 2                | 5  | 100 % |
|                                    | 0.00 %             | 60 %              | 40 %             | 100% |
| Gemazr & oxaliplatin               | 0                  | 1                 | 1                | 2  | 100 % |
|                                    | 0.00 %             | 50 %              | 50 %             | 100% |
| Gemazr & cyclophosphamide          | 0                  | 4                 | 1                | 5  | 100 % |
|                                    | 0.00 %             | 80 %              | 20 %             | 100% |
|                                   | 19                 | 34                | 9                | 62 | 14.5 %|
|                                   | 30.6 %             | 54.8 %            | 14.5 %           | 100% |

Table: 5 show the histopathological types of ovarian cancer.
| Histopathological types                        | Frequency | %    |
|-----------------------------------------------|-----------|------|
| Serous cyst adenocarcinoma                    | 56        | 90.3 |
| Mucinous adenocarcinoma                       | 2         | 3.2  |
| Transitional cell adenocarcinoma              | 1         | 1.6  |
| Endometrial adenocarcinoma                    | 1         | 1.6  |
| Serous papillary adenocarcinoma               | 1         | 1.6  |
| Clear cell carcinoma                          | 1         | 1.6  |
| **Total**                                     | **62**    | **100** |

**Figures**

**Figure 1**

Fig: 1 demonstrates the age distribution of the patients.
Figure 2

Fig: 2 the geographical distribution of the patients treated with second line chemotherapy platinum resistant ovarian cancer in Sudan.
Figure 3

Fig: 3 show the time interval in all the between the complete course of the second line platinum resistance chemotherapy and the disease recurrence.

Figure 4

Fig: 4 show the second line platinum resistance chemotherapy to the ovarian cancer patients.